Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00572481 · ClinicalTrials.gov registry record · Phase 2
Axillary Reverse Mapping
A Phase 2 study of Cancer of the Breast, sponsored by University of Arkansas.
- Active
- Registry status
- Phase 2
- Development phase
- 1,000
- Enrollment target
- 1
- Study location
NCT00572481 is a Phase 2 study of Cancer of the Breast that is active but no longer recruiting, run by University of Arkansas. The registered enrollment target is 1,000 participants, above the 114-participant average among 15 other Cancer of the Breast trials with a reported enrollment target (777% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00572481, a Phase 2 study of Cancer of the Breast, is active but no longer recruiting, sponsored by University of Arkansas.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 1,000 participants
- Enrollment target
- 1
- Study location
Study Summary
We hypothesize that variations in anatomic location of the arm lymphatic drainage system put the arm lymphatics at risk for disruption during a SLNB and / or ALND. Therefore, mapping the drainage of the arm during the procedure would decrease the likelihood of inadvertent disruption of the lymphatics and the subsequent development of lymphedema. A combination of radioactivity and blue dye will be used.
Conditions Studied
Interventions
- PROCEDURE Axillary Reverse Mapping
Study Locations (1)
Arkansas
- University of Arkansas For Medical Sciences - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2007-05 |
| Est. Completion | 2027-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00572481
The ClinicalTrials.gov registry entry for NCT00572481 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 114-participant average among 15 other Cancer of the Breast trials with a reported enrollment target (777% higher). The listed sponsor is University of Arkansas, which has 318 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cancer of the Breast appearing as the primary indexed condition, and to 1 intervention - of which Axillary Reverse Mapping is the first listed.
NCT00572481 reports 1 study location spanning 1 distinct geographic area - top geographies include Arkansas.
Frequently Asked Questions
What is clinical trial NCT00572481 about?
NCT00572481 is a clinical study titled "Axillary Reverse Mapping". We hypothesize that variations in anatomic location of the arm lymphatic drainage system put the arm lymphatics at risk for disruption during a SLNB and / or ALND. Therefore, mapping the drainage of the arm during the procedure would decrease the likelihood of inadvertent disruption of the lymphatic...
What is the current status of trial NCT00572481?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 1,000 participants. The study started on 2007-05. Estimated completion is 2027-11.
What conditions does trial NCT00572481 study?
This clinical trial studies the following conditions: Cancer of the Breast.
What interventions are being tested in trial NCT00572481?
The interventions under investigation include: Axillary Reverse Mapping (PROCEDURE).
Who is sponsoring clinical trial NCT00572481?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00572481 being conducted?
This trial has 1 study location across Arkansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer of the Breast
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Daance FOR Chemotherapy-induced Neuropathy
RECRUITING · Phase 2
-
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
RECRUITING · Phase 2
-
NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer
RECRUITING · Phase 2
-
Proton Radiation for Stage II/III Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Comparing Letrozole Given Alone to Letrozole Given With Avastin in Post-Menopausal Women Breast Cancer
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.